SC-4017, LOXO-RET-18036 (J2G-OX-JZJJ), A Phase 1/2 study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors
What is the goal of the study?
This is a multi-center, open-label, Phase 1/2 study in pediatric patients with an activating RET alteration and an advanced solid or primary Central Nervous System tumor. LOXO-292 will be administered orally twice daily (BID), with the dose adjusted by body surface area (BSA).
Who can participate in the study?
Please contact the study team listed below to learn more.